Randomized Phase 2 Study Testing Hemp-Derived Cannabidiol for Harm Reduction in Young Adults Who Regularly Use Cannabis

What this Trial Is About

Researchers are evaluating the effects of hemp-derived cannabidiol CBD in young adults aged 18 to 25 who regularly use cannabis but are not seeking treatment. The study focuses on the potential harm-reducing properties of CBD on cannabis use disorder CUD symptoms, mood, cognitive function, and psychotic experiences. This randomized, placebo-controlled trial uses a naturalistic approach where participants continue using their preferred cannabis products while being monitored. Participants will be randomly assigned to receive either 400 mg of broad-spectrum CBD or an inactive placebo, taken orally twice daily with food, over an 8-week period. The study includes two groups based on the type of cannabis product used flower or concentrates. Researchers will assess both longer-term effects over 8 weeks and acute effects at specific intervals using a mobile lab setting. During the study, participants will undergo blood testing to measure THC and other cannabinoids, complete mood and cognitive assessments, and report on cannabis use and symptoms. Evaluations occur at baseline, 4 weeks, 8 weeks, and a follow-up at 12 weeks to monitor persistence of effects. The study aims to track changes in cannabis self-administration, symptoms of CUD, mental health, and cognitive function while ensuring participants maintain their usual cannabis use patterns.

A Study of Cannabidiol in Young Adult Cannabis Users